Alliance Pharma PLC - AGM Statement

RNS Number:8760C

Alliance Pharma PLC

12 May 2006

For immediate release 12 May 2006

ALLIANCE PHARMA PLC

('Alliance' or 'the Company')

AGM Statement

Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company, held its Annual General Meeting earlier today at which all resolutions were duly passed.

Michael Gatenby, the Company's Chairman, made the following comments: 'I am pleased to report that trading for the year to date is in line with management expectations. We are benefiting from the recent acquisition of the Hydromol range of dermatology products and we continue to look for further appropriate opportunities to bring additional products into our portfolio.

'Our pipeline products are moving closer to regulatory submission. Phase III clinical trials are on-going and, as part of our pre-marketing activities, we continue to work closely with leading clinicians and recently held a successful symposium on the use of melatonin for sleep disorders held last month at the Royal Society of Medicine in London.'

For further information:

Alliance Pharma plc + 44 (0)1249 466 966

John Dawson, Chief Executive

Maddy Scott, Finance Director

www.alliancepharma.co.uk

Buchanan Communications + 44 (0)20 7466 5000

Mark Court/Lisa Baderoon/Rebecca Skye Dietrich

Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a strong track record of acquiring the rights to established niche brands and owns, or shares, the rights to 30 branded pharmaceutical products and continues to explore opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of conditions and include brands used in periodontitis (a serious gum disease), the prevention of heart disease, in Parkinson's disease, in nutrition, in nasal infections, in the treatment of dermatological conditions and in childbirth.

Alliance Pharma's sales are mainly prescription driven. Its products are distributed to hospitals directly and to UK and International pharmaceutical wholesalers which service both hospital and retail pharmacies with their prescription requirements.

Alliance Pharma is also developing Posidorm for sleep disorders and Isprelor for the induction of labour.

Alliance Pharma joined the AIM market of the London Stock Exchange in December

2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange